ULTOMIRIS^® inhibits the complement component 5 (C5) – a key driver of damage to the NMJ in gMG.^1,4

Complement activation plays a critical role in the pathophysiology of anti–AChR antibody–positive gMG.^4,5

• The binding of anti–AChR antibodies to the AChR triggers activation of the complement system⁵
• Terminal complement activation results in the cleavage of C5 into C5a and C5b⁴
• C5a leads to inflammation, while C5b binds to other complement proteins to form the MAC⁴
• MAC formation results in damage to the NMJ^4,5

ULTOMIRIS^® is designed to target the complement system, a key mediator of NMJ damage^1,5

• ULTOMIRIS^® is a monoclonal antibody that inhibits C5, preventing its cleavage into C5a and C5b^1,5
• This prevents formation of the MAC¹

AChR, acetylcholine receptor; C5, complement component 5; gMG, generalised myasthenia gravis; MAC, membrane attack complex; NMJ, neuromuscular junction.

Adverse Event Reporting

Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com